180 Life
ATNF

From January 1, 2025 to March 31, 2025 Conversion of Series B Convertible Preferred Stock Cancelled shares Shares issued for settlement of liabilities Stock-based compensation

Common stock offered 1,200,000 shares of Common Stock by the company

From June 30, 2024 to September 30, 2024 Shares issued for settlement of liabilities

From March 31, 2024 to June 30, 2024 Shares issued for settlement of liabilities

From January 1, 2024 to March 31, 2024 Adjustment related to reverse stock split Shares issued from exercise of pre-funded warrants related to Amendment to August 2023 Offering

Life Sciences Corp. announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-19.

From June 30, 2023 to September 30, 2023 Shares issued for professional services to directors Shares issued from exercise of August 2023 pre-funded warrants Shares issued in connection with August 2023 Offering, net

Securities offered 666,925 shares of Common Stock by the company

From March 31, 2023 to June 30, 2023 Share issued in connection with April 2023 Offering, net Shares issued from exercise of April 2023 pre-funded warrants

Common Stock offered 400,000 shares by the company

From January 1, 2022 to December 31, 2022 Adjustments related to reverse stock-split Shares issued from exercise of July 2022 pre-funded warrants Shares issued in connection with July 2022 Offering Shares issued from exercise of December 2022 pre-funded warrants Shares issued in connection with December 2022 Offering Shares issued for professional services to directors Stock-based compensation

Common Stock offered by the company 215,000 shares of Common Stock

180 Life Sciences Corp. announced that it will effect a one-for-20 reverse stock split (“reverse split”) of its common stock, $0.0001 par value per share (“Common Stock”), that will become effective on December 19, 2022 at 12:01 a.m. EST. The reverse split will reduce the number of shares of Common Stock issued and outstanding from approximately 40.5 million to approximately 2.0 million.

From June 30, 2022 to September 30, 2022 Shares issued for professional services to directors Shares issued from exercise of pre-funded warrants Shares issued in connection with July 2022 Offering

1.Common stock offered by 3,500,000 shares of common stock 2.The number of shares of common stock to be outstanding after this offering is based on 34,143,823 shares of common stock outstanding as of July 17, 2022

From January 1, 2022 to March 31, 2022 Shares issued for directors’ and professional fees

From January 1, 2021 to December 31, 2021 Shares issued upon conversion of KBL debt Shares issued upon conversion of 180 debt Shares issued in connection with the financing, net of financing costs Shares issued upon exchange of common stock equivalents Shares issued to settle accounts payable Shares issued in connection with the August 2021 Offering, net of financing costs Shares issued to settle convertible debt and derivative liabilities with Alpha Capital Shares issued in connection with the repayment of related party loans and convertible notes Stock based compensation: Common stock Shares Cancelled

From June 30, 2021 to September 30, 2021 Shares issued in connection with the August 2021 Offering, net of financing costs Shares issued to settle convertible debt and derivative liabilities with Alpha Capital Shares issued in connection with the repayment of related party loans and convertible notes Shares issued upon exchange of common stock equivalents Stock based compensation: Common stock

From March 31, 2021 to June 30, 2021 Shares issued to settle accounts payable Impact of transfer agent reconciliation Common stock

From January 1, 2021 To March 31, 2021 Shares issued upon conversion of KBL debt Shares issued upon conversion of 180 debt Shares issued in connection with the private offering, net of financing costs Shares issued upon exchange of common stock equivalents Stock based compensation: Common stock

From January 1, 2020 To December 31, 2020 Common stock issued for cash Shares issued upon conversion of KBL debt Shares issued upon conversion of 180 debt Shares issued upon the conversion of the Series A convertible preferred stock Shares issued upon exchange of common stock equivalents Stock based compensation:Common stock Effect of reverse recapitalization, net of cash acquired

From June 30, 2020 to September 30, 2020 Change in value of common stock subject to possible redemption Issuance of commitment shares and leak-out shares and beneficial conversion feature in connection with convertible promissory notes

From March 31, 2020 to June 30, 2020 Change in value of common stock subject to possible redemption Issuance of commitment shares and leak-out shares and beneficial conversion feature in connection with convertible promissory notes

from December 31, 2018 to December 31, 2019 Common stock subject to possible redemption

From March 31, 2019 to June 30, 2019 Change in value of common stock subject to possible redemption

From January 1, 2019 to April 1, 2019 Change in value of common stock subject to possible redemption On March 5, 2019, the Company’s stockholders approved to extend the period of time for which the Company is required to consummate a Business Combination until June 7, 2019 or such earlier date as determined by the Company’s board of directors. The number of shares of common stock presented for redemption in connection with the Extension Amendment was 5,128,523. The Company paid cash in the aggregate amount of $52,829,304, or approximately $10.30 per share, to redeeming stockholders. As a result of the payment on the shares of common stock presented for redemption in connection with the Extension Amendment, cash and marketable securities held in the Trust Account decreased to $65,633,068. In addition, on March 8, 2019, an aggregate of $573,433 was loaned to the Company and distributed as a cash payment to stockholders that did not redeem their Public Shares, which amount is equal to $0.09 for each of the 6,371,477 Public Shares that were not redeemed.

From January 1, 2017 to June 30, 2017 Sale of 11,500,000 Units, net of underwriting discount and offering expenses Sale of 502,500 Private Units Common stock subject to redemption

from September 7, 2016 to December 31, 2016 Issuance of common stock to Sponsor